Journal Article
. 2009 Feb;12(3).
doi: 10.1159/000189624.

Pharmacogenomics and public health

D Veenstra 1 W Burke  
Affiliations
  • PMID: 19204414
  •     14 References
  •     3 citations

No abstract available

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
L Wang, R Weinshilboum.
Oncogene, 2006 Mar 22; 25(11). PMID: 16550163
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
David L Veenstra, Julie Harris, +3 authors, Carolyn Watts.
Genet Med, 2007 Dec 13; 9(10). PMID: 18073583
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
M P Goetz, A Kamal, M M Ames.
Clin Pharmacol Ther, 2007 Sep 21; 83(1). PMID: 17882159    Free PMC article.
Review.
Warfarin pharmacogenetics.
Nita A Limdi, David L Veenstra.
Pharmacotherapy, 2008 Aug 30; 28(9). PMID: 18752379    Free PMC article.
Review.
Pharmacogenetics in Europe: barriers and opportunities.
D Gurwitz, E Zika, +2 authors, D Ibarreta.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204415
Researchers' perceptions of the ethical implications of pharmacogenomics research with children.
D Avard, T Silverstein, G Sillon, Y Joly.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204423    Free PMC article.
Pharmacogenomics, evidence, and the role of payers.
P A Deverka.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204417    Free PMC article.
The potential of a placebo/nocebo effect in pharmacogenetics.
S B Haga, L R Warner, J O'Daniel.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204418    Free PMC article.
Assessing patient readiness for the clinical adoption of personalized medicine.
A M Issa, W Tufail, +2 authors, M Poonam Baliga.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204419
Pharmacogenomics and the challenge of health disparities.
S S Lee.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204420
The disruptive nature of personalized medicine technologies: implications for the health care system.
R J Carlson.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204421
Will pharmacogenomics disrupt the U.S. health care system? No.
L P Garrison.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204422
Review.
Trends in pharmacogenomic epidemiology: 2001-2007.
I Guessous, M Gwinn, +3 authors, M J Khoury.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204416
End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.
Vural Ozdemir, Erik Fisher, +4 authors, Louise Warnich.
Curr Pharmacogenomics Person Med, 2012 May 01; 10(1). PMID: 22545073    Free PMC article.
Is individualized medicine more cost-effective? A systematic review.
Maximilian H M Hatz, Katharina Schremser, Wolf H Rogowski.
Pharmacoeconomics, 2014 Feb 28; 32(5). PMID: 24574059
Systematic Review.
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.
Susan R Snyder, Jing Hao, +11 authors, Marc S Williams.
Public Health Genomics, 2019 Jun 13; 21(5-6). PMID: 31189173    Free PMC article.